ImunonIMNN
Market Cap: $14.5M
About: Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Employees: 33
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
0.38% more ownership
Funds ownership: 3.59% [Q1] → 3.97% (+0.38%) [Q2]
6% less funds holding
Funds holding: 18 [Q1] → 17 (-1) [Q2]
18% less capital invested
Capital invested by funds: $542K [Q1] → $442K (-$100K) [Q2]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Emily Bodnar 32% 1-year accuracy 29 / 92 met price target | 1,286%upside $14 | Buy Reiterated | 15 Aug 2024 |
HC Wainwright & Co. Emily Bodnar 32% 1-year accuracy 29 / 92 met price target | 1,286%upside $14 | Buy Maintained | 5 Aug 2024 |